0A9E Stock Overview
A biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
CureVac N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.62 |
| 52 Week High | US$5.28 |
| 52 Week Low | US$2.23 |
| Beta | 2.51 |
| 1 Month Change | -11.35% |
| 3 Month Change | 42.62% |
| 1 Year Change | 4.09% |
| 3 Year Change | -77.99% |
| 5 Year Change | n/a |
| Change since IPO | -96.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A9E | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.3% | 0.7% | 0.3% |
| 1Y | 4.1% | -12.4% | 10.4% |
Return vs Industry: 0A9E exceeded the UK Biotechs industry which returned -12.1% over the past year.
Return vs Market: 0A9E underperformed the UK Market which returned 10.4% over the past year.
Price Volatility
| 0A9E volatility | |
|---|---|
| 0A9E Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A9E's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A9E's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,086 | Alexander Zehnder | www.curevac.com |
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer.
CureVac N.V. Fundamentals Summary
| 0A9E fundamental statistics | |
|---|---|
| Market cap | US$818.75m |
| Earnings (TTM) | -US$292.16m |
| Revenue (TTM) | US$69.11m |
11.8x
P/S Ratio-2.8x
P/E RatioIs 0A9E overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A9E income statement (TTM) | |
|---|---|
| Revenue | €65.86m |
| Cost of Revenue | €152.13m |
| Gross Profit | -€86.27m |
| Other Expenses | €192.16m |
| Earnings | -€278.43m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.24 |
| Gross Margin | -131.00% |
| Net Profit Margin | -422.77% |
| Debt/Equity Ratio | 0% |
How did 0A9E perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 16:46 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CureVac N.V. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charlie Yang | BofA Global Research |
| Alec Stranahan | BofA Global Research |
| Geoffrey Meacham | BofA Global Research |